Skip to main content
. Author manuscript; available in PMC: 2020 Nov 1.
Published in final edited form as: Drug Alcohol Depend. 2019 Sep 16;204:107557. doi: 10.1016/j.drugalcdep.2019.107557

Table 2.

Respiratory diagnosis prevalence in cannabis-using vs. matched control cohort and cannabis-use ORs for total, non-TUD, and TUD samples for Asthma (a), COPD (b) and Pneumonia (c)

a. Asthma
Sample Prevalence* (Cannabis vs. Control) Odds Ratio (95% CI), p-value aOR (95% CI), p-value
Total Sample (N=17,864) 10.2% vs. 7.3% 1.44 (1.29 – 1.61), p < 0.0001 2.13 (1.75 – 2.59), p < 0.0001
TUD Subgroup (N=9,356) 14.3% vs. 9.6% 1.57 (1.37 – 1.80), p < 0.0001 1.50 (1.28 – 1.76), p < 0.0001
Non-TUD Subgroup (N=8,508) 5.9% vs. 4.6% 1.32 (1.08 – 1.62), p = 0.0066 1.86 (1.30 – 2.66), p < 0.0001
b. COPD
Sample Prevalence* (Cannabis vs. Control) Odds Ratio (95% CI), p-value aOR (95% CI), p-value
Total Sample (N=17,864) 8.1% vs. 5.4% 1.56 (1.38 – 1.76), p < 0.0001 2.88 (2.20 – 3.76), p < 0.0001
TUD Subgroup (N=9,356) 14.1% vs. 9.0% 1.66 (1.45 – 1.90), p < 0.0001 1.44 (1.20 – 1.73), p < 0.0001
Non-TUD Subgroup (N=8,508) 2.1% vs. 1.0% 2.17 (1.50 – 3.13), p < 0.0001 6.95 (3.02 – 16.01), p < 0.0001
c. Pneumonia
Sample Prevalence* (Cannabis vs. Control) Odds Ratio (95% CI), p-value aOR (95% CI), p-value
Total Sample (N=17,864) 6.4% vs. 3.7% 1.80 (1.56 – 2.08), p < 0.0001 3.44 (2.62 – 4.51), p < 0.0001
TUD Subgroup (N=9,356) 9.7% vs. 5.5% 1.84 (1.56 – 2.16), p < 0.0001 2.60 (1.92 – 3.53), p < 0.0001
Non-TUD Subgroup (N=8,508) 3.0% vs. 1.4% 2.13 (1.56 – 2.91), p < 0.0001 8.35 (4.23 – 16.47), p < 0.0001
*

Prevalence is the prevalence of the diagnosis in the cannabis-using versus matched control cohorts. aOR=adjusted Odds Ratio; bold= statistically significant (p < 0.05) effect.